Vizsgálati helyszín
London
London, London, City of NW1 2BU, Egyesült KirályságMég nincs intézményhez kötve
- 18futó vizsgálat
- 6lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2. fázis8 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz9 vizsgálat
- Toboroz8 vizsgálat
- Lezárult5 vizsgálat
- Meghívásos bevonás1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Sanofi20 vizsgálat
- Genzyme, a Sanofi Company2 vizsgálat
- Bioverativ, a Sanofi company1 vizsgálat
- Sanofi Pasteur, a Sanofi Company1 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213· 2. fázis· Sanofi· Forrás
Toboroz
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009· 3. fázis· Sanofi· Forrás
Toboroz
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031· 2. fázis· Sanofi· Forrás
Toboroz
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234· 1/2. fázis· Sanofi· Forrás
Toboroz
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931· 3. fázis· Sanofi· Forrás
Toboroz
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222· 3. fázis· Sanofi· Forrás
Toboroz
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
NCT06975722· 2. fázis· Sanofi· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
NCT06958536· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· 2. fázis· Sanofi· Forrás
Meghívásos bevonás
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05222906· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
NCT04910776· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575· 3. fázis· Bioverativ, a Sanofi company· Forrás
Fut, nem toboroz
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
NCT03019406· 2. fázis· Genzyme, a Sanofi Company· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek